News InflaRx flatlines after skin disease drug flops in midstage ... Shares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug IFX-1 in a debilitating skin disease.
News Radiopharma firm Telix abandons Nasdaq listing plans Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan.
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.